In particular, reductions in peripheral CD4+ T lymphocytes are commonly observed in advanced cases of pancreatic cancer, melanoma, non-Hodgkin lymphoma, sarcoma, hepatocellular carcinoma, and breast cancer [32]. This evidence concerns the gene CD4 and sarcoma.